2016 Press Releases

Keyword Search
 

2017 | 2016 | 2015
DateTitle 
12/22/16Avinger Announces New FDA Clearance for Lumivascular Imaging Console, Enabling Vessel Measurement Via Touchscreen
Technology Upgrade to Lightbox L250 Allows Physicians to Accurately Assess Luminal Gain REDWOOD CITY, Calif., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that the company has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Lightbox L250 imaging console. With this new FDA clearance, the Lightbox L250 now provides detailed measurement of v... 
Printer Friendly Version
11/03/16Avinger Announces Third Quarter 2016 Results
Revenue of $5.3 Million Increases 95% From Third Quarter 2015 REDWOOD CITY, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the third quarter ended September 30, 2016. Third Quarter and Recent Highlights Revenue of $5.3 million, a 95% increase compared to the third quarter of 2015 Added 17 Lumivascular™ accounts, expanding the install... 
Printer Friendly Version
10/27/16Avinger to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company will be participating in two upcoming investor conferences. Avinger’s management is scheduled to present at the Stephens Fall Investment Conference in New York, NY on Tuesday, November 8, 2016 at 1:00pm ET. Avinger’s management is also scheduled to present at the Canaccord Genuity Medical Technolog... 
Printer Friendly Version
10/25/16Avinger Launches Upgraded Lightbox Imaging Console
Enhancements Bring Greater Efficiency and Ease of Use to Lumivascular™ Platform REDWOOD CITY, Calif., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the U.S. launch of an enhanced version of the company’s Lightbox imaging console. The Lightbox provides a dual display of images to physicians using Avinger’s Lumivascular system, the first-ever image-guided atherectomy and chronic to... 
Printer Friendly Version
10/24/16Avinger to Announce Third Quarter 2016 Results on Thursday, November 3, 2016
Conference call scheduled for Thursday, November 3, 2016 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter of 2016 after the close of trading on Thursday, November 3, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals in... 
Printer Friendly Version
10/20/16Avinger Announces Schedule of Sessions Highlighting Lumivascular Technology at TCT 2016
REDWOOD CITY, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of abstracts and sessions highlighting the Company’s Lumivascular™ technology at the upcoming Transcatheter Cardiovascular Thereaputics (TCT) conference taking place in Washington, DC from October 29-November 2, 2016. Avinger Lumivascular technology highlights at TCT 2016: Complex Revascularizat... 
Printer Friendly Version
10/19/16Avinger Announces Expanded FDA Indications for Pantheris™ as Diagnostic Imaging Device
First-Ever Image-Guided Atherectomy Device Receives Dual Clearance for Diagnostic Imaging and Treatment for Peripheral Artery Disease REDWOOD CITY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that the company has received expanded indications from the U.S. Food and Drug Administration (FDA) recognizing the Pantheris™ Lumivascular atherectomy system as a technology that ... 
Printer Friendly Version
09/13/16Avinger Signs Agreement with U.S. Department of Veterans Affairs for Lumivascular Technology
REDWOOD CITY, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced the company has received an FSS Contract Award from the U.S. Department of Veterans Affairs (VA) which establishes terms under which VA hospitals across the country may acquire Avinger’s portfolio of Optical Coherence Tomography (OCT) image-guided catheters for their veterans hospitals. VA operates the nation's larges... 
Printer Friendly Version
09/07/16Avinger Signs Agreement with HealthTrust for Lumivascular Technology
REDWOOD CITY, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced it has signed an agreement with HealthTrust. The agreement establishes terms under which members of the HealthTrust group purchasing organization may acquire Avinger’s portfolio of technologies designed to treat PAD, including Avinger’s PantherisTM Optical Coherence Tomography (OCT) image-guided atherectomy system, which... 
Printer Friendly Version
08/16/16Avinger, Inc. Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
REDWOOD CITY, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’s common stock at a price to the public of $3.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,285,800 shares of Avinger’s common stock. The tota... 
Printer Friendly Version
08/11/16Avinger, Inc. Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the pricing of its public offering of 8,572,000 shares of its common stock at a price to the public of $3.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,285,800 additional shares of its common stock. The Company expects to close the offerin... 
Printer Friendly Version
08/10/16Avinger, Inc. Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that it intends to offer, subject to market and other conditions, newly issued shares of common stock, $0.001 par value (the "Offering" with such shares being the "Shares") in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange ... 
Printer Friendly Version
08/09/16Avinger, Inc. Announces Participation in Canaccord Genuity 36th Annual Growth Conference
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company plans to participate in the Canaccord Genuity 36th Annual Growth Conference in Boston. Avinger management is scheduled to present on Wednesday, August 10, 2016 at 1:00pm ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger’s websit... 
Printer Friendly Version
08/01/16Avinger, Inc. Announces Second Quarter 2016 Results
REDWOOD CITY, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the second quarter ended June 30, 2016. Second Quarter Highlights Revenue of $4.7 million, a 54% increase compared to the second quarter of 2015 Added 19 lumivascular accounts, the most in a single quarter, expanding the installed base of the Company's lumivascular platform to... 
Printer Friendly Version
07/25/16Avinger, Inc. to Announce Second Quarter 2016 Results on Monday, August 1, 2016
Conference call scheduled for Monday, August 1, 2016 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2016 after the close of trading on Monday, August 1, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interes... 
Printer Friendly Version
07/12/16Avinger, Inc. Announces Preliminary Second Quarter 2016 Revenue Results
Management to host conference call today at 2:00pm PT/5:00pm ET REDWOOD CITY, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that based on preliminary unaudited financial results, it expects total revenue of approximately $4.7 million for the second quarter ended June 30, 2016, an increase of 57% from the second quarter of 2015.   Revenues from disposable devices were $... 
Printer Friendly Version
06/27/16Highmark Health’s VITAL Program to Evaluate Avinger’s Novel Treatment for Peripheral Artery Disease
Innovative Program Studies Full Impact of New Health Technologies PITTSBURGH and REDWOOD CITY, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Highmark Health, Allegheny Health Network (AHN) and Avinger, Inc. (NASDAQ:AVGR) announced a collaboration today to evaluate Pantheris™, Avinger’s novel image-guided atherectomy device for the treatment of peripheral artery disease (PAD). The partnership is part of Highmark Health’s VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovati... 
Printer Friendly Version
06/15/16Avinger, Inc. Announces Drawdown of $10 Million Under Term Loan Facility with CRG
Additional funding to support commercialization of Pantheris™ REDWOOD CITY, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it has completed its second drawdown under the previously announced term loan facility with CRG LP (formerly known as Capital Royalty) and its affiliate funds ("CRG") for proceeds of $10 million before closing fees. The term loan facility gives th... 
Printer Friendly Version
05/04/16Avinger, Inc. Announces First Quarter 2016 Results
Initial sales of Pantheris™ image-guided atherectomy system drive strong revenue growth REDWOOD CITY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31, 2016. First Quarter Highlights Received FDA clearance and began commercialization of an enhanced version of the Pantheris™ image-guided atherectomy system on March 1, 2016 ... 
Printer Friendly Version
04/27/16Avinger, Inc. to Announce First Quarter 2016 Results on Wednesday, May 4, 2016
Conference call scheduled for Wednesday, May 4, 2016 at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the first quarter of 2016 after the close of trading on Wednesday, May 4, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET. Individuals interested ... 
Printer Friendly Version
03/01/16Avinger, Inc. Announces Fourth Quarter and Full Year 2015 Results
Pantheris™ Commercial Launch Underway REDWOOD CITY, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2015. Recent Highlights Commenced commercialization of an enhanced version of the Pantheris™ image-guided atherectomy system following receipt of a 510(k) clearance from the United States Food and Drug Ad... 
Printer Friendly Version
03/01/16Avinger Announces FDA Clearance and U.S. Launch of Breakthrough Treatment for Patients With Peripheral Artery Disease
Pantheris First-Ever Image-Guided Atherectomy Device Designed to Empower Physicians to Precisely Remove Plaque While Avoiding Disruption of Normal Arterial Wall Structures REDWOOD CITY, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the company has received 510(k) clearance from the United States Food and Drug Administration (FDA) for an enhanced version of its Panth... 
Printer Friendly Version
02/23/16Avinger, Inc. to Present Cowen and Company 36th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that the company plans to present at the Cowen and Company 36th Annual Health Care Conference in Boston. Avinger management is scheduled to present on Tuesday, March 8, 2016 at 8:40am ET. Interested ... 
Printer Friendly Version
02/18/16Avinger, Inc. to Announce Fourth Quarter and Year-End 2015 Results on Tuesday, March 1, 2016
Conference Call Scheduled for Tuesday, March 1, 2016, at 1:30pm PT/4:30pm ET REDWOOD CITY, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease, today announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Tuesday, M... 
Printer Friendly Version
01/04/16Avinger, Inc. Names Joseph Rafferty as Vice President of Sales
REDWOOD CITY, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today announced that Joseph Rafferty has been named Vice President of Sales, effective January 4, 2016. Mr. Rafferty will report directly to Avinger's CEO, Jeff Soinski. Mr. Rafferty joins Avinger with more than 30 ... 
Printer Friendly Version